{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:26:12Z","timestamp":1793805972724,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.05.027","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:24:20Z","timestamp":1781688260000},"page":"173-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Paris System for reporting urinary cytology in the follow-up of non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9166-531X","authenticated-orcid":false,"given":"Otto","family":"Jokelainen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liida","family":"Ruotsalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essi","family":"Ikonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo K.","family":"Nykopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2026.05.027_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.05.027_bib0002","series-title":"Cancer in Finland 2022","author":"Pitk\u00e4niemi","year":"2024"},{"key":"10.1016\/j.urolonc.2026.05.027_bib0003","series-title":"TNM classification of malignant tumours","author":"Brierley","year":"2017"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.027_bib0004","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.027_bib0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.027_bib0006","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.027_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jasc.2020.04.015","article-title":"The Paris System \u201catypical urothelial cells\u201d category: can the current criteria be improved?","volume":"10","author":"Vosoughi","year":"2021","journal-title":"J Am Soc Cytopathol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.027_bib0008","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/bju.15418","article-title":"Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert\u00ae Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer","volume":"128","author":"Cowan","year":"2021","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.027_bib0009","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.euf.2022.02.006","article-title":"Reducing the frequency of follow-up cystoscopy in low-grade pTa non\u2013muscle-invasive bladder cancer using the ADXBLADDER biomarker","volume":"8","author":"Roupr\u00eat","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.05.027_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.832835","article-title":"Xpert Bladder Cancer Monitor may avoid cystoscopies in patients under \u201cactive surveillance\u201d for recurrent bladder cancer (BIAS Project): longitudinal cohort study","volume":"12","author":"Fasulo","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.027_bib0011","doi-asserted-by":"crossref","first-page":"108.e19","DOI":"10.1016\/j.urolonc.2021.11.013","article-title":"The bladder EpiCheck test and cytology in the follow-up of patients with non-muscle-invasive high-grade bladder carcinoma","volume":"40","author":"Pierconti","year":"2022","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.027_bib0012","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.euo.2025.04.020","article-title":"Results of the prospective randomized UroFollow trial comparing marker-guided versus cystoscopy-based surveillance in patients with low\/intermediate-risk bladder cancer","volume":"8","author":"Schmitz-Dr\u00e4ger","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.027_bib0013","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","article-title":"Use of the Xpert Bladder Cancer Monitor urinary biomarker test for guiding cystoscopy in high-grade non\u2013muscle-invasive bladder cancer: results from the randomized controlled DaBlaCa-15 trial","volume":"88","author":"Dreyer","year":"2025","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.027_bib0014","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.027_bib0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000527980","article-title":"Evaluation of the implementation and diagnostic accuracy of the Paris Classification for reporting urinary cytology in voided urine specimens: a cyto-histological correlation study in a cancer center","volume":"90","author":"Lobo","year":"2023","journal-title":"Pathobiology."},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.027_bib0016","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000446270","article-title":"The Paris System for Reporting Urinary Cytology: the quest to develop a standardized terminology","volume":"60","author":"Barkan","year":"2016","journal-title":"Acta Cytol"},{"key":"10.1016\/j.urolonc.2026.05.027_bib0017","series-title":"The Paris system for reporting urinary cytology","author":"Wojcik","year":"2022"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.027_bib0018","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jasc.2020.10.002","article-title":"Experience on the use of the Paris System for reporting urinary cytopathology: review of the published literature","volume":"10","author":"Pastorello","year":"2021","journal-title":"J Am Soc Cytopathol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.027_bib0019","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.eururo.2003.11.019","article-title":"Biopsy of the red patch at cystoscopy: is it worthwhile?","volume":"45","author":"Swinn","year":"2004","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.027_bib0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ajur.2022.12.006","article-title":"The natural course of bacillus Calmette\u2013Gu\u00e9rin-induced bladder lesions: a long-term follow-up study and systematic review","volume":"10","author":"Ma","year":"2023","journal-title":"Asian J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.027_bib0021","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bju.14470","article-title":"Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacillus Calmette\u2013Gu\u00e9rin (BCG) treatment","volume":"123","author":"Nurminen","year":"2019","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.027_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.475","article-title":"The significance of isolated de novo red patches in the bladder in patients referred with suspected urinary tract cancer: results from the IDENTIFY study","volume":"6","author":"Khadhouri","year":"2025","journal-title":"BJUI Compass"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.027_bib0023","first-page":"18","article-title":"The usage of the Paris classification system in urine cytology in the diagnosis of non-muscle-invasive bladder cancer: a retrospective single-center study","volume":"16","author":"Saarinen","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.urolonc.2026.05.027_bib0024","series-title":"IBM SPSS statistics for windows","year":"2020"},{"key":"10.1016\/j.urolonc.2026.05.027_bib0025","series-title":"RStudio: integrated development for R","year":"2020"},{"key":"10.1016\/j.urolonc.2026.05.027_bib0026","series-title":"R: a language and environment for statistical computing","year":"2022"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.027_bib0027","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/jpm12020170","article-title":"The Paris System for Reporting Urinary Cytology: a meta-analysis","volume":"12","author":"Nikas","year":"2022","journal-title":"J Pers Med"},{"issue":"9","key":"10.1016\/j.urolonc.2026.05.027_bib0028","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncy.22726","article-title":"Atypical urothelial cells classified according to the Paris System for Reporting Urinary Cytology: a 2-year experience with histological correlation from a Finnish tertiary care center\u2014Low rate and high risk of malignancy","volume":"131","author":"P\u00f6yry","year":"2023","journal-title":"Cancer Cytopathol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:29:47Z","timestamp":1793802587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005521"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.027","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Paris System for reporting urinary cytology in the follow-up of non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}